The influence of 2'-fucosyllactose on intestinal cell function: A comprehensive review of experimental studies
DOI:
https://doi.org/10.31989/ffhd.v15i10.1675Abstract
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal illnesses that causes preterm neonates to die. This occurs because Toll-like receptor 4 (TLR4) is activated by lipopolysaccharides, and preterm newborns' intestines express TLR4 at far greater levels than those of full-term neonates. NEC occurs in approximately 1 out of every 1,000 live births, with 5% to 10% incidence, and over 90% of cases are observed in infants younger than one month. Certain elements in breast milk have been found to help lower the risk of NEC. This systematic review aims to analyze various experimental studies related to the administration of 2’-Fucosyllactose (2'FL) that have the potential to induce improvement and therapy in NEC cases through intestinal cell function. There have not been many systematic reviews that specifically highlight the therapeutic effects of 2'FL on Necrotizing Enterocolitis (NEC), most of which still address the role of human milk oligosaccharides (HMOs). The results show that the search flow uses the PRISMA Flowchart; after screening 133 titles and abstracts, 55 studies were accessed to verify the feasibility of the full text. Overall, there were 5 studies selected in this study for a comprehensive review. According to the study's findings, 2'-FL, one of the HMOs, has a number of advantageous impacts on the host's immune system and digestive tract. Among many other advantages, HMOs have been shown to boost the immunological response to vaccinations, influence the makeup of the gut microbiota, and enhance the expression of genes related to gut function.
Keywords: NEC, HMOs, 2'-FL, Intestine, TLR4.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Functional Foods in Health and Disease - Online ISSN: 2160-3855; Print ISSN: 2378-7007
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.